Solomon Woldu, MD
Urology · Dallas, TXNPI 1518284462
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,123 of the $48,773 with a category attached, or 82.3%. Urogen Pharma, Inc. accounts for 83.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2022 at $26,235 and has fallen 79.3% since, to $5,441 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $455.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$41K
- Photocure Inc$850
- Johnson & Johnson$737
- AstraZeneca$698
- Myriad Genetic Laboratories, Inc.$489
- Conmed Corporation$389
- plus $5K from 29 others
Across 72 payments — averaging $16,629 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Ferring Pharmaceuticals AS$19K
- Urogen Pharma, Inc.$8K
- Organon$3K
What the payments were for
- Consulting fees$40,12382%
- Speaking & faculty fees$1000%
- Food & beverage$8,53818%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 25 | $40,887 |
| Photocure Inc | 9 | $850 |
| Johnson & Johnson(2 entities) | 7 | $737 |
| AstraZeneca | 6 | $698 |
| Myriad Genetic Laboratories, Inc. | 3 | $489 |
| Conmed Corporation | 3 | $389 |
| Dendreon Pharmaceuticals LLC | 3 | $388 |
| Intuitive Surgical | 6 | $364 |
| Biotissue Holdings Inc. | 1 | $361 |
| Blue Earth Diagnostics | 3 | $335 |
| KARL Storz Endoscopy-america | 5 | $311 |
| Profound Medical Corp. | 2 | $304 |
| Novartis | 2 | $276 |
| Boston Scientific | 3 | $267 |
| Foundation Medicine, Inc. | 3 | $198 |
| Medtronic | 2 | $175 |
| Olympus America Inc. | 3 | $166 |
| Immunitybio, Inc. | 1 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $140 |
| Sumitomo Pharma America, Inc. | 1 | $134 |
| Clovis Oncology, Inc. | 1 | $133 |
| AVEO Pharmaceuticals, Inc. | 1 | $132 |
| Myovant Sciences Inc. | 1 | $122 |
| Procept Biorobotics Corporation | 1 | $109 |
| Progenics Pharmaceuticals, Inc. | 1 | $107 |
| Bayer | 1 | $106 |
| Astellas Pharma US Inc | 1 | $104 |
| EMD Serono, Inc. | 1 | $95 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $78 |
| 180 Medical, Inc. | 2 | $39 |
| Convatec Inc. | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 1 | $26 |
| Ferring Pharmaceuticals AS | 1 | $24 |
| Tempus AI, Inc | 1 | $24 |
| Halozyme Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,773 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 19 | $11,467 |
| MyrbetriqMirabegron | 17 | $10,429 |
| EliquisApixaban | 11 | $5,375 |
| Tamsulosin Hcl | 94 | $1,482 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $562 |
| Finasteride | 25 | $385 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $242 |
| Oxybutynin Chloride | 29 | $236 |
| Methocarbamol | 27 | $138 |
| Ciprofloxacin Hcl | 13 | $80 |
| Levofloxacin | 28 | $77 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $56 |
| Tramadol Hcl | 24 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $134 | $11,46719 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $10,42917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.
Other urology in Dallas
- Allen MoreyDallas$914K
- Vitaly MargulisDallas$555K
- Yair LotanDallas$371K
- Claus RoehrbornDallas$169K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.